Regeneron Pharmaceuticals

🇺🇸United States

Country: 🇺🇸United States

Ownership: Public

Established: 1988-01-01

Employees: 13.4K

Market Cap: $132.4B

Website: http://www.regeneron.com

Introduction: Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. Its product portfolio includes the following brands: Dupixent, Evkeeza, Eylea, Inmazeb, and Kevzara. The firm accelerates the traditional drug development process through its proprietary VelociSuite technologies such as VelocImmune, which uses unique genetically humanized mice to produce optimized fully human antibodies and bispecific antibodies. The company was founded by Alferd G. Gilman, Leonard S. Schleifer, George Damis Yancopoulos, and Eric M. Shooter on January 8, 1988, and is headquartered in Tarrytown, NY.

Clinical Trials

A Trial to Learn if Single Ascending Intravenous (IV) Doses of REGN7508 Are Safe and Well Tolerated, and How it Works in the Body of Healthy Adult Participants

Phase 1

Completed

Conditions: Healthy Volunteer

Interventions: Drug: REGN7508 (IV)
Drug: REGN7508 (SC)
Drug: Matching Placebo (SC)
Drug: Matching Placebo (IV)

First Posted Date: 2022-11-02

Last Posted Date: 2024-09-30

Lead Sponsor: Regeneron Pharmaceuticals

Target Recruit Count: 80

Registration Number: NCT05603195

Locations: 🇬🇧
Labcorp Clinical Research Unit, Leeds, United Kingdom

Dupilumab in Adolescent and Adult Skin of Color Participants: Open-label Moderate-to-severe Eczema Trial

Phase 4

Completed

Conditions: Moderate-to-Severe Atopic Dermatitis
Atopic Eczema

Interventions: Drug: dupilumab
Other: Topical emollient (moisturizer)

First Posted Date: 2022-10-21

Last Posted Date: 2024-12-10

Lead Sponsor: Regeneron Pharmaceuticals

Target Recruit Count: 124

Registration Number: NCT05590585

Locations: 🇺🇸
Skin and Cancer Associates, LLP, Miami, Florida, United States
🇺🇸
C2 Research Center, LLC, Montgomery, Alabama, United States
🇺🇸
Oregon Health & Science University, Portland, Oregon, United States

and more 27 locations

A Trial That Evaluates Disease Characteristics in Hemophilia B Adult Male Participants Receiving Prophylaxis With Standard of Care Factor IX Protein (FIX) Replacement Therapy

Recruiting

Conditions: Hemophilia B

Interventions: Other: Non-Interventional

First Posted Date: 2022-10-05

Last Posted Date: 2024-12-24

Lead Sponsor: Regeneron Pharmaceuticals

Target Recruit Count: 120

Registration Number: NCT05568459

Locations: 🇺🇸
Orthopaedic Hemophilia Treatment Center, Los Angeles, California, United States
🇺🇸
University of Colorado Hemophilia and Thrombosis Center, Aurora, Colorado, United States
🇺🇸
Yale HTC, New Haven, Connecticut, United States

and more 15 locations

A Trial to Learn How the Cancer Vaccine BNT116 in Combination With Cemiplimab Works and How Safe the Combination is in Adults With Advanced Non-small Cell Lung Cancer (EMPOWERVAX Lung 1)

Phase 2

Recruiting

Conditions: Advanced Non-Small Cell Lung Cancer

Interventions: Drug: BNT116
Drug: Cemiplimab

First Posted Date: 2022-09-28

Last Posted Date: 2024-11-05

Lead Sponsor: Regeneron Pharmaceuticals

Target Recruit Count: 100

Registration Number: NCT05557591

Locations: 🇺🇸
The Oncology Institute of Hope and Innovation, Los Angeles, California, United States
🇺🇸
University of California Irvine, Orange, California, United States
🇺🇸
Weill Cornell Medical College, New York, New York, United States

and more 52 locations

Assess Gastrointestinal Blood Loss After Receiving Aspirin or Aspirin Plus Rivaroxaban in Healthy Adult Participants

Not Applicable

Completed

Conditions: Healthy Volunteer

Interventions: Drug: Aspirin
Drug: rivaroxaban low dose
Drug: rivaroxaban high dose

First Posted Date: 2022-09-21

Last Posted Date: 2023-05-24

Lead Sponsor: Regeneron Pharmaceuticals

Target Recruit Count: 60

Registration Number: NCT05546957

Locations: 🇬🇧
LabCorp CRU, Leeds, West Yorkshire, United Kingdom

A Precision Medicine Approach Using Gene Silencing to Treat a Chronic Liver Disease Called Non-Alcoholic Steatohepatitis (NASH) in Adult Participants at Increased Genetic Risk for This Condition

Phase 2

Recruiting

Conditions: Non-alcoholic Steatohepatitis (NASH)
Metabolic Dysfunction Associated Steatohepatitis (MASH)

Interventions: Drug: Placebo
Drug: ALN-HSD

First Posted Date: 2022-08-29

Last Posted Date: 2025-01-08

Lead Sponsor: Regeneron Pharmaceuticals

Target Recruit Count: 120

Registration Number: NCT05519475

Locations: 🇺🇸
Evolution Clinical Trials, Hialeah Gardens, Florida, United States
🇺🇸
GI Associates, Flowood, Mississippi, United States
🇺🇸
Columbia University Irving Medical Center, New York, New York, United States

and more 57 locations

A Trial to Learn if a COVID-19 Therapeutic is Safe and Well Tolerated, and How it Works in the Body of Healthy Adult Participants

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: REGN14284
Drug: Matching Placebo

First Posted Date: 2022-08-17

Last Posted Date: 2023-07-27

Lead Sponsor: Regeneron Pharmaceuticals

Target Recruit Count: 48

Registration Number: NCT05505448

Locations: 🇧🇪
Universitair Ziekenhuis Leuven Gasthuisberg Campus, Leuven, Belgium

A Trial to Learn if REGN7999 is Safe and Well Tolerated, and How it Works in the Body of Healthy Participants

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: REGN7999
Drug: Placebo

First Posted Date: 2022-08-01

Last Posted Date: 2024-07-24

Lead Sponsor: Regeneron Pharmaceuticals

Target Recruit Count: 64

Registration Number: NCT05481333

Locations: 🇧🇪
Drug Research Unit Gent, Gent, Belgium

Efficacy of the Anti-Bet v 1 Monoclonal Antibodies (Given Subcutaneously) to Reduce Allergic Rhinitis and Conjunctivitis Symptoms and Skin Test Reactivity Upon Exposure to Birch Allergen in Adult Participants

Phase 2

Completed

Conditions: Allergic Rhinitis
Conjunctivitis

Interventions: Drug: REGN5713
Drug: REGN5715
Drug: REGN5714
Other: Placebo

First Posted Date: 2022-06-24

Last Posted Date: 2024-11-19

Lead Sponsor: Regeneron Pharmaceuticals

Target Recruit Count: 217

Registration Number: NCT05430919

Locations: 🇨🇦
Inflamax Research Limited DBA Cliantha Research, Mississauga, Ontario, Canada
🇨🇦
Kingston General Health Research Institute, Kingston, Ontario, Canada
🇨🇦
Clinique Specialisee en Allergie de la Capitale, Quebec City, Quebec, Canada

Genetic Data Collection in Adult Participants to Identify Genetic Variants of Known Importance in Non-alcoholic Steatohepatitis (NASH)

Not Applicable

Terminated

Conditions: Non-alcoholic Steatohepatitis (NASH)

Interventions: Procedure: No Intervention

First Posted Date: 2022-06-21

Last Posted Date: 2023-03-17

Lead Sponsor: Regeneron Pharmaceuticals

Target Recruit Count: 5311

Registration Number: NCT05423327

Locations: 🇺🇸
Southern California Research Center, Coronado, California, United States
🇺🇸
Velocity Clinical Research, Gardena, California, United States
🇺🇸
UCSD Health System, La Jolla, California, United States

and more 45 locations

Home Terms & Conditions Privacy Policy